Dinara Nurkina

Mrs. Dinara Nurkina

internal medicine, Karaganda State Medical University, Karaganda, Kazakhstan
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
LZLazzat Zhussupbekova
Lazzat Zhussupbekova
Dinara NurkinaDinara Nurkina
Dinara Nurkina
GZGyulnar Zhussupova
Gyulnar Zhussupova
ASAliya Smagulova
Aliya Smagulova
VRVenera Rakhmetova
Venera Rakhmetova
IKIlya Kukes
Ilya Kukes
Cardiovascular disease is a major cause of death worldwide and a global socio-economic problem. To date, there are numerous studies focused on finding new biomarkers of cardiovascular diseases. High-technological methods such as mass spectrometry (MS), high-performance liquid chromatography (HPLC), and nuclear magnetic resonance (NMR) spectroscopy enable us to record thousands of metabolites of organs and tissues. Studying organisms at a molecular level contributes to an in-depth understanding of preclinical conditions of various diseases. Metabolomics reflects the dynamics of metabolism distribution, including environmental influences, allowing us to create a metabolic profile of the patient. The aim of this review was to analyze current data on metabolomic and proteomic biomarkers in the diagnosis of cardiovascular diseases. The search databases were used to select studies on the potential clinical and diagnostic application of proteomic and metabolomic markers in cardiology. The selected sources were subjected to qualitative and thematic analysis. All biomarkers were grouped according to the pathophysiological process (inflammation, blood coagulation and lipid metabolism disorders, myocardial necrosis, etc.). The association of changes in metabolomic and proteomic profiles with the activation of pathogenic processes in the cardiovascular system was demonstrated. The use of these multivariate markers, individually or in combination, will increase the accuracy of early diagnosis and the effectiveness of treatment. This article also highlights the limitations of the method and possible ways to solve them.

4 May 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
LZLazzat Zhussupbekova
Lazzat Zhussupbekova
ABAlina Bulatova
Alina Bulatova
Dinara NurkinaDinara Nurkina
Dinara Nurkina
KKKlara Kurmangaliyeva
Klara Kurmangaliyeva
VRVenera Rakhmetova
Venera Rakhmetova
EAElmira Akhmedyarova
Elmira Akhmedyarova
Over the past decade, the growth of Helicobacter pylori antibiotic resistance has had an increasingly significant impact on the choice of eradication therapy regimens, significantly limiting the number of effective treatment options. The Maastricht VI guidelines consider the use of probiotics as one way to optimise therapy and increase the likelihood of successful eradication. In this regard, the study of the possible mechanisms of action of probiotic preparations on antibiotic-resistant strains of H. pylori, as well as their possible role in preventing the development of resistance, is of considerable interest and may contribute to improving the quality of eradication therapy in the near future. The aim of the study is to determine the role of probiotics in modifying the microbiota during and after eradication therapy, as well as to assess their potential impact on the development of antibiotic resistance. A search for scientific publications was conducted in international and national bibliographic databases: PubMed, Embase, Scopus, Web of Science Core Collection, Google Scholar, and eLIBRARY.ru. The search was conducted in English, Russian, and Kazakh for the period from 26 April 2015 to 14 July 2025. The review includes 41 publications. Eradication therapy has a pronounced negative effect on the intestinal microbiota, leading to disruption of its composition and the development of side effects that reduce treatment tolerability. A number of studies in recent years have demonstrated a link between antibiotic therapy and the development of antibiotic resistance caused by genetic rearrangements and mutations in the gut microbiota genome. As an additional approach to correcting these adverse effects, special attention is paid to the use of probiotics. According to the research results, probiotic preparations help reduce the frequency of side effects of eradication therapy and may increase its effectiveness against antibiotic-resistant strains of H. pylori. The use of probiotic preparations in the treatment of resistant strains of Helicobacter pylori is a promising direction that opens up new opportunities for optimising eradication regimens. However, this approach requires further clinical and experimental studies to confirm its effectiveness and form reasonable prognostic conclusions.

1 October 2024
Verified
Journal Article
Closed access
LZL Zhussupbekova
L Zhussupbekova
Dinara NurkinaDinara Nurkina
Dinara Nurkina
SSS Sarkulova
S Sarkulova
GSG Smailova
G Smailova
KZK Zholamanov
K Zholamanov

1 January 2023
Verified
Journal Article
Closed access
Dinara NurkinaDinara Nurkina
Dinara Nurkina
MBM Baimuratova
M Baimuratova
LZLazzat Zhussupbekova
Lazzat Zhussupbekova
AKA Kodaspayev
A Kodaspayev
SAS Alimbayeva
S Alimbayeva

1 May 2025 in Journal Of Hypertension
Verified
Journal Article
Closed access
Dinara NurkinaDinara Nurkina
Dinara Nurkina
LZLazzat Zhussupbekova
Lazzat Zhussupbekova
MBMairash Baimuratova
Mairash Baimuratova
TJTemirbek Janpaizov
Temirbek Janpaizov
YAYerassyl Akhmetov
Yerassyl Akhmetov

1 May 2024 in Journal Of Hypertension
Verified
Journal Article
Closed access
Dinara NurkinaDinara Nurkina
Dinara Nurkina
LZLazzat Zhussupbekova
Lazzat Zhussupbekova
MBMairash Baimuratova
Mairash Baimuratova
ZSZhasken Smagulov
Zhasken Smagulov
Objective: To study the frequency and structure of hospitalizations of young patients (up to 44 years old, WHO) at the Almaty City Cardiology Center for the period 2018–2022. Design and method: In the course of an observational, descriptive, cross-sectional study, we studied the frequency and structure of reasons for hospitalization in young patients over a five-year period. Results: During the study, it was found that during the designated period, a total of 1827 young patients were hospitalized (average age 36.7 ± 4.4 years), which amounted to 4.8% of the total number of hospitalized patients (n = 38054). Detailing by year, it should be noted that the peak of hospitalizations occurred in 2019 - 8.5%, with a significant decrease in 2020 - 4%, (which may have been due to the COVID-SARS-2 pandemic), while the minimum was recorded in 2018 - 3%. The most common cause of hospitalization (more than 30%) were acute forms of coronary heart disease, while the frequency of hospitalization with unstable angina (23.5%) prevailed over the myocardial infarction (12.2%). The third position was occupied by arterial hypertension - 9.9%. In descending order, the following nosologies followed: cardiomyopathies - 8.1% and acute myocarditis - 5.6%. The top ten most common reasons for hospitalization also included supraventricular tachycardia, atrial fibrillation/flutter, WPW syndrome. Analysis of the frequency of hospitalizations of patients with acute forms of coronary heart disease over the years demonstrated an upward trend. Among all hospitalizations of young patients with myocardial infarction, the most common was, according to the ICD-11 code (I21.0) -42.8%, then in descending order - (I21.1) -25.7%, (I21.4) -12.2%, (I22.1) -7.2%, (I22.0) -6.8% (I22.8) -2.3%. Conclusions: Thus, among all reasons for hospitalization, unstable angina, myocardial infarction and arterial hypertension occupied the three leading positions. Dynamics of the frequency of hospitalization of young patients with acute forms of coronary heart disease had an upward trend. The most common type of myocardial infarction in young people was acute transmural myocardial infarction of the left ventricle, which probably determines the severity of myocardial damage and the unfavorable prognosis in this population.